查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856335

乳癌液態切片檢測設備市場：按技術、應用、最終用戶、檢測類型、檢體類型、適應症和分銷管道分類－2025-2032年全球預測

Breast Cancer Liquid Biopsy Testing Devices Market by Technology, Application, End User, Test Type, Sample Type, Indication, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，乳癌液態切片檢測設備市場規模將達到 44.6 億美元，複合年成長率為 20.19%。

關鍵市場統計數據
基準年 2024 10.2億美元
預計年份：2025年 12.3億美元
預測年份 2032 44.6億美元
複合年成長率 (%) 20.19%

重點關注液態切片檢測在乳癌治療和創新路徑中不斷變化的作用

液態切片技術正從一種小眾研究工具轉變為精準腫瘤學的關鍵組成部分，為檢測腫瘤來源的生物標記提供了微創的組織切片檢查替代方案。隨著臨床團隊尋求更快、更安全、更可重複的方法來監測腫瘤動態，液態切片設備為改善早期檢測、指導治療選擇和追蹤微量殘存疾病提供了機會。本文首先概述了循環腫瘤DNA、循環性腫瘤細胞和細胞外囊泡（如外泌體）的科學基礎，並解釋了檢測的敏感度、特異性和通量如何影響其臨床應用。

從實驗室研究到臨床應用的轉變需要檢測平台、樣本處理流程和資料解讀框架的協調一致。監管路徑和報銷政策也會影響推廣應用的進程，而供應商在檢測驗證、自動化和互通性的投入將決定其競爭地位。最終，相關人員必須權衡技術性能、工作流程相容性、成本效益和臨床效用，才能真正實現液態切片活體組織切片設備在乳癌常規管理中的應用前景。

變革性轉變正在重塑乳癌液態切片檢測的技術、臨床實踐和商業化。

由於檢測化學、設備靈敏度和生物資訊學的進步，液態切片檢測設備領域正在迅速改變。用於檢測低頻變異的高解析度技術以及結合ctDNA、CTC和外泌體成分的多分析方法正在擴大其臨床應用範圍。同時，樣本處理和標準化的改進降低了分析前變異性，從而實現了更可靠的縱向監測。這些技術進步與不斷完善的臨床指引相輔相成，後者日益認知到微創診斷在治療選擇和疾病監測方面的價值。

在商業方面，診斷開發人員、臨床實驗室和腫瘤中心之間的策略合作正在加速證據產生和真實世界檢驗。合作夥伴優先考慮可擴展的工作流程和雲端分析，以支援分散式檢查和遠端監測。此外，支付方的討論正轉向基於價值的報銷模式，優先考慮那些能夠顯著改善治療效果或降低後續成本的診斷方法。總而言之，這些轉變正在促進科學成熟度和商業性準備的融合，從而改變臨床醫生和醫療系統進行乳癌檢測和管理的方式。

評估2025年美國關稅變化對診斷設備製造商供應鏈、成本和策略採購的累積影響

美國近期關稅調整正對整個醫療設備供應鏈產生連鎖反應，迫使診斷設備製造商重新評估籌資策略和成本結構。數位PCR和定序設備的關鍵組件，例如微流體晶片、特殊聚合物和半導體光學元件，可能面臨更高的到岸成本，迫使供應商評估近岸外包、雙重採購或重新設計以替換組件等方案。對於垂直整合的試劑和耗材供應商而言，關稅帶來的價格壓力可能會影響其利潤率，並加速與代工製造商的談判，以確保長期供應協議的達成。

為應對這些壓力，一些機構正在加強供應商資格審核和庫存管理，同時加快對本地製造能力的投資，以降低風險。監管機構和物流團隊也在更緊密地合作，以確保試劑供應的連續性，並最大限度地減少對臨床檢測服務的干擾。因此，採購決策不再僅基於單位成本，而是同時考慮供應彈性、前置作業時間和庫存承載能力，進而影響整個診斷生態系統的長期策略規劃。

關鍵細分洞察，重點在於技術選擇、應用、使用者環境、檢體方法、樣本工作流程、臨床適應症和通路。

我們的細分分析揭示了技術創新和應用正在整合的領域，以及為何某些平台在特定應用場景中更受青睞。我們的技術細分比較了數位PCR、次世代定序和即時PCR ，評估了基於晶片和液滴的數位PCR形式、標靶定序、全外EXOME定序和全基因組定序等次世代定序，以及基於染料和基於探針的即時PCR。這些差異對於分析靈敏度、多重檢測能力和單次檢測成本至關重要，而這些因素反過來又會影響臨床應用。

應用細分評估循環性腫瘤細胞、循環腫瘤DNA和外泌體，其中外泌體進一步細分為外泌體DNA和外泌體RNA。最終使用者細分主要針對合約研究組織、診斷實驗室、醫院/診所和研究中心，每個機構對通量、週轉時間和法規遵循都有不同的要求。檢測類型細分區分體外診斷設備與試劑與實驗室自建檢測方法。體外診斷設備分為儀器和試劑兩類，而實驗室自建檢測方法通常分為基於NGS的LDT和基於PCR的LDT，每種方法都有其自身的驗證和商業化路徑。

檢體類型細分將血漿、血清和全血作為影響產量比率和檢測性能的重要分析前變數進行分析。適應症細分區分了早期檢測、預後、復發檢測和治療監測等不同的臨床終點，這些終點驅動著檢測方法的選擇和證據的產生。最後，銷售管道細分對比了直銷、線上銷售和第三方分銷商，並認知到線上銷售是透過電子商務平台和製造商網站進行的，這會影響通路策略、定價和客戶支援。整合這些細分觀點有助於供應商明確其研發、監管工作和商業性資源應集中在哪些方面，從而使產品特性與最終用戶需求和臨床價值相符。

關鍵區域洞察解釋了主要全球區域的採納動態、醫療保健系統優先事項和法律規範如何差異，以及這些差異如何影響部署策略。

區域動態將影響液態切片檢測設備的採用、報銷以及在腫瘤診療路徑中的整合方式。在美洲，臨床網路和學術中心通常推動早期臨床檢驗和應用，並得到分散式檢查基礎設施和蓬勃發展的私人檢測產業的支持。同時，在歐洲、中東和非洲，統一的監管環境和公共報銷框架影響液體活體組織切片設備的採用，集中式參考實驗室與支付方合作，以證明其健康經濟價值。在亞太地區，基因組學基礎設施的快速投資、不斷擴大的臨床試驗活動以及多樣化的公共和私人醫療模式，為集中式和即時檢測解決方案創造了機會。

這些區域差異會影響產品設計，從儀器尺寸和試劑低溫運輸要求到語言本地化以及與電子健康記錄的整合，無一例外。因此，打入市場策略也必須因地制宜。一些地區優先考慮廣泛的臨床效用數據和衛生技術評估，而其他地區則更注重成本效益和可擴展部署。與區域實驗室網路、關鍵意見領袖和當地監管夥伴關係建立策略合作夥伴關係，對於推動臨床應用以及與不同地區的支付方成功談判至關重要。

對競爭對手進行競爭考察，整合競爭提案、差異化策略和聯盟模式，進而塑造診斷藥物研發公司的競爭格局。

領先的診斷公司和新興的專業公司正在採取互補策略來實現產品差異化。一些公司專注於平台層面的整合，將高靈敏度儀器與專有試劑和雲端基礎分析結合，建構能夠吸引實驗室客戶的穩固生態系統。另一些公司則專注於特定的臨床適應症和檢體類型，最佳化檢測化學方法，用於早期檢測和微小殘留病灶監測，在這些領域，超高的靈敏度和特異性至關重要。受託研究機構和臨床服務實驗室也發揮關鍵作用，它們在監管部門核准之前，為新型檢測方法提供驗證流程和規模化生產能力。

技術提供者、學術中心和腫瘤網路之間的夥伴關係已成為產生臨床證據並加速將其納入指南的主要途徑。策略性併購和授權協議不斷重塑能力結構，使一些供應商能夠填補生物資訊學、樣本處理和全球分銷方面的空白。在選擇合作夥伴和供應商時，決策者必須權衡技術優勢、證據產生能力和商業覆蓋範圍，以實現永續的臨床和商業性成果。

為尋求擴大臨床應用、最佳化產品市場契合度並維持液態切片檢測領域競爭優勢的行業領導者提供切實可行的建議

為了將科學進步轉化為商業性成功，產業領導者應優先考慮與特定臨床應用案例相符的策略性證據產生。設計能夠證明產品在早期檢測、復發檢測或治療監測方面具有更高臨床價值的試驗，並儘早與關鍵意見領袖合作，共同製定臨床路徑。同時，應投資穩健的分析前工作流程以及與實驗室資訊系統的互通性，以最大限度地減少醫院實驗室和參考中心採用該產品的障礙。製造商還應評估混合商業化策略，將面向高觸感客戶的直接銷售與線上通路和分銷商關係相結合，以擴大市場覆蓋範圍。

在營運方面，透過多元化採購、在地化生產或簽訂長期供應商協議來增強供應鏈韌性，可以降低關稅和物流風險。在產品方面，應優先考慮模組化和軟體升級，使儀器能夠隨著生物資訊學的發展而演進，而無需更換硬體。最後，應制定與支付方合作的策略，將診斷定位為價值促進因素，並合作進行結果研究和真實世界證據研究，以支持報銷談判和長期應用。

本報告的調查方法闡述了支撐研究結果和見解的跨學科方法、資料三角驗證和檢驗步驟。

調查方法整合了專家文獻綜述、監管和政策分析以及結構化的相關人員參與，以確保觀點平衡且切實可行。主要資訊來源包括對臨床專家、實驗室主任、採購人員和行業高管的訪談，以了解實踐現狀、應用障礙和商業化策略。二級資訊來源包括同行評審出版物、會議論文集以及公開的監管文件和指導文件，以提供檢測性能和臨床效用的技術說明。

分析人員採用嚴謹的三角驗證流程，交叉檢驗研究結果，並將訪談內容與已發表的證據和產品規格進行比對。在條件允許的情況下，透過記錄研究納入標準、相關人員訪談範圍以及臨床終點解讀的理由，確保調查方法的透明度。這種方法確保了結論既反映了最新的科學認知，也考慮了影響液態切片設備應用和規模化推廣的現實限制。

總結全文，涵蓋機會領域、持續存在的挑戰以及下一階段臨床和商業性開發策略重點。

液態切片設備處於技術、臨床需求和醫療保健系統優先事項的關鍵交匯點。非侵入性檢測腫瘤衍生訊號能力的提升，為改善早期檢測、最佳化預後和加強治療監測提供了實際的機會。然而，要實現這些機會，需要解決技術差異性問題，使證據產生與支付方的期望相符，並確保工作流程與臨床實驗室操作無縫銜接。持續存在的挑戰包括：協調分析前操作流程、證明療效的顯著改善，以及建立能夠反映診斷價值的永續報銷機制。

展望未來，那些能夠將嚴謹的臨床驗證、實用的產品設計以及戰略夥伴關係關係相結合的相關人員，將最有利於把檢測方法轉化為廣泛應用的臨床工具。注重模組化平台、建立穩健的供應鏈以及與監管機構和支付方生態系統的合作，將加速檢測方法的應用。總而言之，下一階段需要研發人員、臨床醫生、實驗室和醫療保健系統共同努力，將前景看好的技術轉化為乳癌診療的常規組成部分。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧演算法整合到ctDNA分析中，以提高早期檢測的靈敏度
  • 開發一種基於甲基化的超靈敏檢測方法，用於監測乳癌患者的微量殘存疾病
  • 新興的微流體晶片平台能夠快速、高通量地分離循環性腫瘤細胞，用於常規診斷。
  • 臨床上將ctDNA和外泌體RNA合併分析應用於轉移性乳癌的個人化治療決策
  • 監管核准和報銷途徑將加速下一代液態切片技術的市場准入
  • 診斷公司與製藥公司在標靶治療伴隨診斷的合作
  • 標準化工作主要集中在分析前工作流程上，以減少不同實驗室間液態切片樣本處理的差異。
  • 開發一種用於門診和家庭環境中分散式乳癌監測的即時液態切片設備
  • 整合多體學工作流程，結合蛋白質體學和基因生物標記，以提高早期乳癌篩檢的特異性
  • 將液態切片結果與人工智慧主導的數位病理學相結合，以實現全面的腫瘤分析和預後評估。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章乳癌液態切片檢測設備市場（依技術分類）

  • 數位PCR
    • 基於晶片的數位PCR
    • 液滴式數位PCR
  • 下一代定序
    • 標靶定序
    • 全EXOME定序
    • 全基因組定序
  • 即時PCR
    • 基於染料的PCR
    • 基於探針的PCR

第9章乳癌液態切片檢測設備市場（按應用領域分類）

  • 循環性腫瘤細胞
  • 循環腫瘤DNA
  • 外泌體
    • 外泌體DNA
    • 外泌體RNA

第10章乳癌液態切片檢測設備市場（以最終用戶分類）

  • 受託研究機構
  • 診斷實驗室
  • 醫院和診所
  • 研究中心

第11章乳癌液態切片檢測設備市場（依檢測類型分類）

  • 體外診斷
    • 裝置
    • 試劑
  • 實驗室自建測試
    • 基於NGS的LDT
    • 基於PCR的LDT

第12章乳癌液態切片檢測設備市場（依樣本類型分類）

  • 電漿
  • 血清
  • 全血

第13章乳癌液態切片檢測設備市場（依適應症分類）

  • 早期檢測
  • 預後
  • 復發檢測
  • 治療監測

第14章乳癌液態切片檢測設備市場（依通路分類）

  • 直銷
  • 線上銷售
    • 電子商務平台
    • 製造商網站
  • 第三方經銷商

第15章乳癌液態切片檢測設備市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章乳癌液態切片檢測設備市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 各國乳癌液態切片檢測設備市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche AG
    • Guardant Health, Inc.
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • Natera, Inc.
    • Qiagen NV
    • Bio-Rad Laboratories, Inc.
    • Sysmex Corporation
    • Grail, Inc.
    • Epigenomics AG
Product Code: MRR-742BD517C0D8

The Breast Cancer Liquid Biopsy Testing Devices Market is projected to grow by USD 4.46 billion at a CAGR of 20.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.02 billion
Estimated Year [2025] USD 1.23 billion
Forecast Year [2032] USD 4.46 billion
CAGR (%) 20.19%

A focused introduction to the evolving role of liquid biopsy testing in breast cancer care and innovation pathways

Liquid biopsy technologies have moved from niche research tools to pivotal components of precision oncology, offering minimally invasive alternatives to tissue biopsies for detecting tumor-derived biomarkers. As clinical teams seek faster, safer, and more repeatable modalities to monitor tumor dynamics, liquid biopsy testing devices present opportunities to improve early detection, guide therapeutic selection, and track minimal residual disease. This introduction sets the stage by clarifying the scientific underpinnings-circulating tumor DNA, circulating tumor cells, and extracellular vesicles such as exosomes-and by describing how assay sensitivity, specificity, and throughput shape clinical applicability.

Transitioning from bench to bedside requires alignment across assay platforms, sample handling protocols, and data interpretation frameworks. Regulatory pathways and reimbursement considerations further influence adoption timelines, while vendor investments in assay validation, automation, and interoperability determine competitive positioning. Ultimately, stakeholders must balance technical performance with workflow compatibility, cost-efficiency, and clinical utility to realize the promise of liquid biopsy testing devices in routine breast cancer management.

Transformative shifts reshaping technology, clinical practice, and commercialization in breast cancer liquid biopsy testing

The landscape of liquid biopsy testing devices has undergone rapid transformation driven by advances in assay chemistry, instrument sensitivity, and bioinformatics. High-resolution techniques that detect low-frequency variants and multi-analyte approaches combining ctDNA, CTCs, and exosomal content are expanding clinical use cases. Concurrently, improvements in sample processing and standardization have reduced pre-analytical variability, enabling more reliable longitudinal monitoring. These technical gains are complemented by evolving clinical guidelines that increasingly recognize the value of minimally invasive diagnostics for treatment selection and disease surveillance.

On the commercialization front, strategic collaborations between diagnostic developers, clinical laboratories, and oncology centers are accelerating evidence generation and real-world validation. Partners are prioritizing scalable workflows and cloud-enabled analytics to support decentralized testing and remote monitoring. Moreover, payer dialogue has shifted toward value-based reimbursement for diagnostics that demonstrably improve outcomes or reduce downstream costs. Taken together, these shifts create a convergence of scientific maturity and commercial readiness that is changing how clinicians and health systems approach breast cancer detection and management.

Assessing the cumulative impact of United States tariff changes in 2025 on supply chains, costs, and strategic sourcing for diagnostic device manufacturers

Recent tariff adjustments in the United States have reverberated across medical device supply chains, prompting diagnostic manufacturers to reassess sourcing strategies and cost structures. Components such as microfluidic chips, specialty polymers, and semiconductor-based optics that are integral to digital PCR and sequencing instruments may face higher landed costs, compelling vendors to evaluate nearshoring, dual sourcing, or redesign for component substitution. For vertically integrated suppliers of reagents and consumables, tariff-induced price pressure can affect margin profiles and may accelerate negotiations with contract manufacturers to secure long-term supply agreements.

In response to these pressures, some organizations are intensifying supplier qualification and inventory management practices while accelerating investments in local manufacturing capabilities to mitigate exposure. Regulatory and logistics teams are also collaborating more closely to ensure continuity of reagent supply and to minimize disruptions to clinical testing services. As a result, procurement decisions increasingly weigh not only unit cost but also supply resilience, lead times, and inventory carrying implications, shaping longer-term strategic planning across the diagnostic ecosystem.

Key segmentation insights that illuminate technological choices, applications, user environments, testing approaches, specimen workflows, clinical indications, and distribution pathways

Segmentation analysis clarifies where innovation and adoption are concentrated and why certain platforms gain traction in specific use cases. Technology segmentation compares digital PCR, next generation sequencing, and real time PCR, with digital PCR further differentiated into chip based and droplet digital formats, next generation sequencing spanning targeted sequencing, whole exome sequencing, and whole genome sequencing, and real time PCR evaluated across dye based and probe based chemistries. These distinctions matter for analytical sensitivity, multiplexing capacity, and cost per assay, which in turn influence clinical uptake.

Application segmentation assesses circulating tumor cells, circulating tumor DNA, and exosomes, with exosomes further disaggregated into exosomal DNA and exosomal RNA; each analyte class offers distinct biological insight and requires tailored extraction and analysis workflows. End user segmentation highlights contract research organizations, diagnostic laboratories, hospitals and clinics, and research centers as primary adopters, with differing demands for throughput, turnaround time, and regulatory compliance. Test type segmentation contrasts in vitro diagnostic instruments and reagents against laboratory developed tests, noting that in vitro diagnostics split into instrument and reagent categories while laboratory developed tests are often grouped as NGS based LDTs and PCR based LDTs, each with unique validation and commercialization pathways.

Sample type segmentation examines plasma, serum, and whole blood as critical pre-analytical variables that affect yield and assay performance. Indication segmentation differentiates early detection, prognosis, recurrence detection, and treatment monitoring as distinct clinical endpoints that drive assay selection and evidence generation. Finally, distribution channel segmentation contrasts direct sales, online sales, and third party distributors, recognizing that online sales may occur via e-commerce platforms or manufacturer websites, which impacts channel strategy, pricing, and customer support. Integrating these segmentation perspectives reveals where vendors should concentrate R&D, regulatory efforts, and commercial resources to align product features with end-user needs and clinical value.

Key regional insights that explain how adoption dynamics, health system priorities, and regulatory frameworks vary across major global regions and influence deployment strategies

Regional dynamics shape how liquid biopsy testing devices are adopted, reimbursed, and integrated with oncology pathways. In the Americas, clinical networks and academic centers often drive early clinical validation and adoption, supported by infrastructure for decentralized testing and an active private laboratory sector. Meanwhile, Europe, Middle East & Africa presents a heterogeneous landscape where regulatory harmonization efforts and public reimbursement frameworks influence uptake, and where centralized reference laboratories collaborate with healthcare payers to demonstrate health economic value. In Asia-Pacific, rapid investments in genomics infrastructure, expanding clinical trial activity, and diverse public-private healthcare models create opportunities for both centralized and point-of-care solutions.

These regional differences affect product design, from instrument footprint and reagent cold-chain requirements to language localization and integration with electronic health records. Market entry strategies must therefore be tailored: some regions prioritize extensive clinical utility data and health technology assessments, whereas others emphasize cost-efficiency and scalable deployment. Strategic partnerships with regional laboratory networks, key opinion leaders, and local regulatory experts are essential to accelerate clinical adoption and to navigate payer negotiations across these varied geographies.

Key company insights that synthesize competitive offers, differentiation strategies, and collaboration patterns shaping the competitive landscape for diagnostic developers

Leading diagnostic companies and emerging specialists are pursuing complementary approaches to differentiate their offerings. Some firms emphasize platform-level integration-pairing high-sensitivity instruments with proprietary reagents and cloud-based analytics-to create defensible ecosystems that lock in laboratory customers. Other organizations focus on niche clinical indications or specimen types, optimizing assay chemistry for early detection or minimal residual disease monitoring where ultra-high sensitivity and specificity are prerequisites. Contract research organizations and clinical service laboratories also play a critical role, providing validation pipelines and scaling capabilities for novel assays prior to regulatory clearance.

Partnerships between technology providers, academic centers, and oncology networks have become a primary vehicle for generating clinical evidence and accelerating guideline inclusion. Strategic M&A activity and licensing agreements continue to reconfigure capability stacks, enabling some vendors to bridge gaps in bioinformatics, sample processing, or global distribution. For decision-makers, choosing partners and suppliers involves balancing technical merit, evidence generation capacity, and commercialization reach to achieve durable clinical and commercial outcomes.

Actionable recommendations for industry leaders aiming to scale clinical adoption, optimize product-market fit, and sustain competitive advantage in liquid biopsy testing

To translate scientific advances into commercial success, industry leaders should prioritize strategic evidence generation that aligns with specific clinical use cases. Design studies that demonstrate incremental clinical value in early detection, recurrence detection, or therapy monitoring, and engage key opinion leaders early to shape clinical pathways. In parallel, invest in robust pre-analytical workflows and interoperability with laboratory information systems to minimize barriers to adoption among hospital laboratories and reference centers. Manufacturers should also evaluate hybrid commercialization approaches that combine direct sales for high-touch accounts with online channels and distributor relationships to broaden reach.

Operationally, strengthening supply chain resilience through diversified sourcing, local manufacturing options, or longer-term supplier agreements will reduce exposure to tariff and logistics risks. From a product perspective, prioritize modularity and software-enabled upgrades so instruments can evolve with bioinformatic advances without requiring full hardware replacement. Finally, pursue payer engagement strategies that frame diagnostics as value drivers, collaborating on outcomes studies and real-world evidence generation to support reimbursement conversations and long-term adoption.

Research methodology that explains the multidisciplinary approach, data triangulation, and validation steps underpinning the report's findings and insights

The research methodology integrates technical literature review, regulatory and policy analysis, and structured stakeholder engagement to ensure a balanced and actionable perspective. Primary inputs include interviews with clinical experts, laboratory directors, procurement leads, and industry executives to capture operational realities, adoption barriers, and commercialization strategies. Secondary sources span peer-reviewed publications, conference proceedings, and publicly available regulatory filings and guidance documents to ground technical statements about assay performance and clinical utility.

Analysts conducted a rigorous triangulation process to cross-validate findings, reconciling interview insights with published evidence and product specifications. Where possible, methodological transparency was maintained by documenting inclusion criteria for studies, the scope of stakeholder interviews, and the rationale for interpreting clinical endpoints. This approach ensures that conclusions reflect both the latest scientific understanding and real-world constraints that influence implementation and scale-up of liquid biopsy testing devices.

Concluding synthesis that encapsulates opportunity areas, persistent challenges, and strategic priorities for the next phase of clinical and commercial development

Liquid biopsy testing devices occupy a pivotal intersection of technology, clinical need, and health system priorities. The growing capability to detect tumor-derived signals noninvasively presents tangible opportunities to improve early detection, refine prognosis, and enhance treatment monitoring. Nonetheless, realization of these opportunities hinges on addressing technical variability, aligning evidence generation with payer expectations, and ensuring that workflows integrate seamlessly with clinical laboratory operations. Persistent challenges include harmonizing pre-analytical practices, demonstrating clear outcome improvements, and creating sustainable reimbursement pathways that reflect the diagnostic's value contribution.

Looking ahead, stakeholders who combine rigorous clinical validation, pragmatic product design, and strategic partnerships will be best positioned to translate assays into widely adopted clinical tools. Emphasizing modular platforms, resilient supply chains, and engagement with regulatory and payer ecosystems will accelerate adoption. In sum, the next phase requires coordinated action across developers, clinicians, laboratories, and health systems to transform promising technologies into routine components of breast cancer care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence algorithms for ctDNA analysis to improve early detection sensitivity
  • 5.2. Development of ultrasensitive methylation-based assays for minimal residual disease monitoring in breast cancer patients
  • 5.3. Emergence of microfluidic chip platforms enabling rapid high-throughput isolation of circulating tumor cells in routine diagnostics
  • 5.4. Clinical adoption of combined ctDNA and exosomal RNA profiling for personalized treatment decision support in metastatic breast cancer
  • 5.5. Regulatory approvals and reimbursement pathways accelerating market access for next-generation liquid biopsy tests
  • 5.6. Partnerships between diagnostics firms and pharmaceutical companies for companion diagnostics in targeted therapies
  • 5.7. Standardization initiatives focused on pre-analytical workflows to reduce variability in liquid biopsy sample processing across laboratories
  • 5.8. Advancement of point-of-care liquid biopsy devices for decentralized breast cancer monitoring in outpatient and home settings
  • 5.9. Integration of multi-omics workflows combining proteomic and genomic biomarkers to enhance specificity in early breast cancer screening
  • 5.10. Expansion of AI-driven digital pathology integration with liquid biopsy results for comprehensive tumor profiling and prognostic assessment

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Breast Cancer Liquid Biopsy Testing Devices Market, by Technology

  • 8.1. Digital PCR
    • 8.1.1. Chip Based Digital PCR
    • 8.1.2. Droplet Digital PCR
  • 8.2. Next Generation Sequencing
    • 8.2.1. Targeted Sequencing
    • 8.2.2. Whole Exome Sequencing
    • 8.2.3. Whole Genome Sequencing
  • 8.3. Real Time PCR
    • 8.3.1. Dye Based PCR
    • 8.3.2. Probe Based PCR

9. Breast Cancer Liquid Biopsy Testing Devices Market, by Application

  • 9.1. Circulating Tumor Cells
  • 9.2. Circulating Tumor DNA
  • 9.3. Exosomes
    • 9.3.1. Exosomal DNA
    • 9.3.2. Exosomal RNA

10. Breast Cancer Liquid Biopsy Testing Devices Market, by End User

  • 10.1. Contract Research Organizations
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals And Clinics
  • 10.4. Research Centers

11. Breast Cancer Liquid Biopsy Testing Devices Market, by Test Type

  • 11.1. In Vitro Diagnostic
    • 11.1.1. Instruments
    • 11.1.2. Reagents
  • 11.2. Laboratory Developed Test
    • 11.2.1. NGS Based LDT
    • 11.2.2. PCR Based LDT

12. Breast Cancer Liquid Biopsy Testing Devices Market, by Sample Type

  • 12.1. Plasma
  • 12.2. Serum
  • 12.3. Whole Blood

13. Breast Cancer Liquid Biopsy Testing Devices Market, by Indication

  • 13.1. Early Detection
  • 13.2. Prognosis
  • 13.3. Recurrence Detection
  • 13.4. Treatment Monitoring

14. Breast Cancer Liquid Biopsy Testing Devices Market, by Distribution Channel

  • 14.1. Direct Sales
  • 14.2. Online Sales
    • 14.2.1. E Commerce Platforms
    • 14.2.2. Manufacturer Website
  • 14.3. Third Party Distributors

15. Breast Cancer Liquid Biopsy Testing Devices Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Breast Cancer Liquid Biopsy Testing Devices Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Breast Cancer Liquid Biopsy Testing Devices Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. F. Hoffmann-La Roche AG
    • 18.3.2. Guardant Health, Inc.
    • 18.3.3. Illumina, Inc.
    • 18.3.4. Thermo Fisher Scientific Inc.
    • 18.3.5. Natera, Inc.
    • 18.3.6. Qiagen N.V.
    • 18.3.7. Bio-Rad Laboratories, Inc.
    • 18.3.8. Sysmex Corporation
    • 18.3.9. Grail, Inc.
    • 18.3.10. Epigenomics AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CHIP BASED DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DROPLET DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DYE BASED PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROBE BASED PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CIRCULATING TUMOR DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EXOSOMAL RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY IN VITRO DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY NGS BASED LDT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PCR BASED LDT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY PROGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY RECURRENCE DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY TREATMENT MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY E COMMERCE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MANUFACTURER WEBSITE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MANUFACTURER WEBSITE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MANUFACTURER WEBSITE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MANUFACTURER WEBSITE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MANUFACTURER WEBSITE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY MANUFACTURER WEBSITE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL BREAST CANCER LIQUID BIOPSY TESTING DEVICES MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL BREAST C